70-gene signature impacts treatment decisions in breast CA

70-gene signature impacts treatment decisions in breast CA

(HealthDay)—The 70-gene signature (GS) assay affects treatment decisions among physicians treating patients identified as being at intermediate risk with the 21-gene assay (21-GA), according to a study published online Oct. 26 in JAMA Oncology.

Michaela Tsai, M.D., from the Virginia Piper Cancer Center in Minneapolis, and colleagues conducted a study involving 840 patients with and a 21-gene assay recurrence score of 18 to 30. Physicians were given the 70-GS result before adjuvant , and the change in physician was assessed before versus after receiving the result.

The researchers found that receiving the 70-GS classifications was correlated with a significant change in adjuvant treatment decision, with an odds ratio of 0.64 for all patients. Overall, 28.9 percent of low-risk patients had chemotherapy removed from the treatment recommendation, while 36.7 percent of high-risk patients had chemotherapy added. Results of the 70-GS were associated with the physician's adjuvant treatment recommendation; 87.8 percent of high-risk and 90.6 percent of low-risk patients were recommended to receive or no chemotherapy, respectively. In 78.6 percent of cases, physicians reported having more confidence in their treatment recommendations based on 70-GS results.

"The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6 percent)," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Agendia Inc., which funded the study.


Explore further

70-gene signature not cost-effective in breast cancer

More information: Abstract/Full Text
Journal information: JAMA Oncology

Copyright © 2017 HealthDay. All rights reserved.

Citation: 70-gene signature impacts treatment decisions in breast CA (2017, October 29) retrieved 9 August 2020 from https://medicalxpress.com/news/2017-10-gene-signature-impacts-treatment-decisions.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments